Editas Medicine Announces Chief Financial Officer Transition

Erick J. Lucera to Step Down as CFO to pursue another opportunity

Senior Vice President of Finance Amy Parison Appointed CFO

CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy Parison will succeed Mr. Lucera as Chief Financial Officer.

Read more at globenewswire.com